Oncotelic Therapeutics, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Oncotelic Therapeutics, Inc. (OTLC) is a clinical-stage biopharmaceutical company focused on developing therapies for orphan oncology indications, infectious diseases, and neurological disorders; its core pipeline includes OT-101, an antisense oligonucleotide targeting TGF-β2 in Phase 3 trials for pancreatic cancer and Phase 2 for glioblastoma, with applications in viruses like COVID-19 and pediatric diffuse intrinsic pontine glioma (DIPG); OXi4503, a vascular disrupting agent in Phase 2 for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS); CA4P (fosbretabulin), a vascular disrupting agent repositioned for advanced melanoma including rare pediatric cases; AL-101, an intranasal apomorphine delivery system in Phase 2 for Parkinson's disease, erectile dysfunction, and female sexual dysfunction; and emerging assets such as Deciparticle nanomedicine platform candidates, 4P fosretabulin, OT-102 for Alzheimer's, and AI-enhanced technologies for drug development. Founded in 1988 and headquartered in Agoura Hills, California, the company operates primarily in the United States with global clinical trial collaborations and targets patient populations with high unmet needs in oncology, virology, and neurology. Recent developments include a November 2025 joint venture milestone with GMP Bio, where an independent Frost & Sullivan valuation pegged the pipeline at $1.7 billion, advancing OT-101 into Phase 3 pancreatic ductal adenocarcinoma trials and expanding the GMP-licensed manufacturing facility in San Diego; progression of multiple programs highlighted in September 2025 updates, such as OXi4503 toward pivotal Phase 3 and nanomedicine assets via the 505(b)(2) pathway; and ongoing preparations for a potential GMP Bio IPO on the Hong Kong Stock Exchange in late 2026.
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer's Disease
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
NetworkNews Audio Announces Audio Press Release (APR) Discussing Advancing Oncology Therapeutics, Strategic Positioning within High-Value Development Pathways